目的 探讨活血止痛胶囊联合骨肽注射液治疗膝骨性关节炎的临床疗效。方法 选取2015年1月-2016年1月在内江市第一人民医院骨科接受治疗的膝骨性关节炎患者78例,根据治疗方案的不同分为对照组(39例)和治疗组(39例),对照组关节腔注射骨肽注射液,30 mg/次,1次/周;治疗组在此基础上口服活血止痛胶囊,6粒/次,2次/d。两组患者均连续治疗4周。比较两组患者治疗前后总有效率。观察两组治疗前后Lequesne指数和视觉模拟分数变化情况,同时检测两组治疗前后血清IL-1β、TNF-α、MMP-9和NO水平改变。结果 治疗后,对照组和治疗组总有效率分别为79.49%和94.87%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者Lequesne指数和视觉模拟分数均明显降低(P<0.05),但治疗组降低的更明显,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清IL-1β、TNF-α、MMP-9和NO水平均明显降低(P<0.05),但治疗组降低的更明显,两组比较差异具有统计学意义(P<0.05)。结论 活血止痛胶囊联合骨肽注射液治疗膝骨性关节炎疗效显著,可明显改善患者膝关节功能和减轻关节疼痛及降低血清炎性因子水平,具有一定的临床推广应用价值。

Objective To observe the clinical effects of amisulpride combined with olanzapine in improvement of cognitive function in patients with schizophrenia. Methods Patients (61 cases) with schizophrenia in Mental Health Center of Baoshan District in Shanghai from October 2013 to October 2015 were randomly divided into control group (31 cases) and treatment group (30 cases). The patients in the control group were po administered with Olanzapine Tablets 10 mg/d at beginning, then gradually added to 15 - 20 mg/d according to patient's condition and symptoms in one week, and the average dosage was (18.75 ± 1.13) mg/d. Patients in the treatment group were po administered with Amisulpride Tablets 0.1 g/d at beginning, then gradually added to 0.1 - 0.3 g/d according to patient's condition in one week, and the average dosage was (0.26 ± 0.06) mg/d. Two groups were treated for 8 weeks. Positive and negative syndrome scale (PANSS), Wechsler memory scale (WMS), and Wisconsin card sorting test (WCST) were compared before and after treatment. Results After treatment for 4 weeks, positive symptom scores, general mental pathological symptom scores, and total scores in both groups were improved significantly (P < 0.05, 0.01). The negative symptom scores and total scores in the treatment group were significantly better than those in the control group, and there were significant differences between two groups (P < 0.05). After treatment for 8 weeks, positive symptom scores, negative symptom scores, general mental pathological symptom scores, and total scores in both groups were improved significantly, and the differences were statistically significant in the same group (P < 0.05). There was no significant difference between two groups. After treatment for 8 weeks, the number of correct responses and categories were significantly increased, but the number of random errors was significantly decreased, and the differences were statistically significant in the same group (P < 0.05). The WCST scores in the treatment group were significantly better than those in the control group, and there were significant differences between two groups (P < 0.05). After treatment for 8 weeks, there was no significant difference between two groups. Conclusion Amisulpride combined with olanzapine has significant clinical curative effect in improvement of cognitive function in patients with schizophrenia, which has a certain clinical application value.